GSK

(IN BRIEF) GSK will present significant research at the 2024 European Respiratory Society (ERS) Congress, including data from phase III trials of its new biologic, depemokimab, for severe asthma. The presentations highlight GSK’s commitment to advancing respiratory medicine, with a … Read the full press release →

(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release →

(IN BRIEF) GSK has announced encouraging findings from the interim analysis of the DREAMM-8 phase III trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex) compared to the standard of care, bortezomib plus PomDex, for relapsed or … Read the full press release →

(IN BRIEF) GSK plc has announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, an oral antibiotic aimed at treating uncomplicated urogenital gonorrhoea in adolescents and adults. The trial demonstrated gepotidacin’s non-inferiority compared to the current … Read the full press release →

(IN BRIEF) GSK plc has finalized the acquisition of Aiolos Bio, bolstering its respiratory biologics portfolio with AIO-001, a promising long-acting anti-TSLP monoclonal antibody for treating asthma. AIO-001, set to enter phase II clinical trials, targets severe asthma patients with … Read the full press release →

(IN BRIEF) GSK plc has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) targeting chronic hepatitis B (CHB). The Fast Track designation aims to expedite the development … Read the full press release →

(IN BRIEF) GSK has received marketing authorization from the European Commission for Omjjara (momelotinib), an oral inhibitor targeting JAK1/JAK2 and activin A receptor type 1 (ACVR1). Omjjara is the first approved treatment in the EU for disease-related splenomegaly (enlarged spleen) … Read the full press release →

(IN BRIEF) GSK has submitted a regulatory application to the European Medicines Agency (EMA) to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. The … Read the full press release →

(IN BRIEF) GSK plc has announced positive results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial, evaluating the use of Jemperli (dostarlimab) in combination with standard chemotherapy and as maintenance therapy for patients with primary advanced or recurrent endometrial … Read the full press release →

(IN BRIEF) In a significant development, GSK plc has received marketing authorization from the European Commission (EC) for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy as a treatment option for adult patients suffering from mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) … Read the full press release →

(IN BRIEF) GlaxoSmithKline (GSK) has reported positive results from the interim efficacy analysis of the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial successfully met its primary endpoint of … Read the full press release →

(IN BRIEF) GSK, a leading pharmaceutical company, has unveiled plans to conduct Phase III trials in 2024 for a low carbon version of its popular inhaler, Ventolin (salbutamol). The initiative aims to reduce greenhouse gas emissions associated with the inhaler’s … Read the full press release →

(IN BRIEF) ViiV Healthcare has received approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), marking the first complete long-acting HIV-1 injectable treatment in China. This approval allows people living with HIV in … Read the full press release →

(IN BRIEF) ViiV Healthcare, a global specialist HIV company, will present 23 abstracts at the 19th Annual European AIDS Conference (EACS 2023). These abstracts will cover various aspects of HIV treatment and prevention, including real-world data on long-acting and 2-drug … Read the full press release →

(IN BRIEF) GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the approval of Jemperli (dostarlimab) in combination with chemotherapy as a frontline treatment for adult … Read the full press release →

(IN BRIEF) Lloyds Banking Group has appointed Suresh Balaji as its Chief Marketing Officer, effective from October 16. In his new role, Balaji will oversee the Brand, Marketing, and Experience function for the group. He will be responsible for developing … Read the full press release →

(IN BRIEF) GlaxoSmithKline (GSK) has announced a confidential settlement in the Cantlay/Harper case filed in California state court, which was scheduled for trial in November 2023. Additionally, GSK has settled the three remaining breast cancer bellwether cases in California, effectively … Read the full press release →